List of Field Safety Notices from 7 to 11 July 2025.
Similar Posts
Medicines: Marketing Authorisation Holders’ submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing
Marketing Authorisation Holders should review their manufacturing processes to identify and, if found, to mitigate the risk of nitrosamine impurities being present.
Standard: Implementation of medical devices future regime
Information on the new regulations for the post-market surveillance of medical devices which come into effect on 16 June 2025.
Medical devices: get regulatory advice from the MHRA
How to apply for a regulatory advice meeting on medical devices and in vitro diagnostic devices.
Corporate report: MHRA: policy for handling corporate conflicts of interest
Information about how we handle potential corporate conflicts of interest (COI) between different parts of the Agency.
Guidance: Innovative Licensing and Access Pathway (ILAP)
The Innovative Licensing and Access Pathway (ILAP) is focused on getting the most transformative new medicines to patients in the UK health system more quickly.
Class 4 Medicines Defect Notification: Erythromycin Stearate BP 250mg Tablets, Amdipharm UK Ltd, EL(25)A/32
Amdipharm UK Ltd has informed MHRA that the Patient information leaflet (PIL) in the cartons for the batch listed in this notification includes a superseded PIL.